|
TOP
|
|
VIEKIRA XR(dasabuvir, ombitasvir, paritaprevir, and ritonavir)extended-release tablets(五)
teractions (7)].
Table 2. Drugs that are Contraindicated with VIEKIRA XR
Drug Class Drug(s) within Class
that are
Contraindicated Clinical Comments
Alpha1-adrenoreceptor
antagonist Alfuzosin HCL Potential for hypotension.
Anti-anginal Ranolazine Potential for serious and/or life-threatening reactions.
Antiarrhythmic Dronedarone Potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Anticonvulsants Carbamazepine,
phenytoin,
phenobarbital VIEKIRA XR exposures may decrease leading to a potential loss of therapeutic activity of VIEKIRA XR.
Anti-gout Colchicine Potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment.
Antihyperlipidemic agent Gemfibrozil Increase in dasabuvir exposures by 10-fold which may increase the risk of QT prolongation.
Antimycobacterial Rifampin VIEKIRA XR exposures may decrease leading to a potential loss of therapeutic activity of VIEKIRA XR.
Antipsychotic Lurasidone
Pimozide Potential for serious and/or life-threatening reactions.
Potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Ergot derivatives Ergotamine, dihydroergotamine, methylergonovine Acute ergot toxicity characterized by vasospasm and tissue ischemia has been associated with co-administration of ritonavir and ergonovine, ergotamine, dihydroergotamine, or methylergonovine.
Ethinyl estradiol-
containing products Ethinyl estradiol-containing medications such as combined oral contraceptives Potential for ALT elevations [see Warnings and Precautions (5.3)].
GI Motility Agent Cisapride Potential for serious and/or life threatening reactions such as cardiac arrhythmias.
Herbal Product St. John’s Wort (Hypericum perforatum) VIEKIRA XR exposures may decrease leading to a potential loss of therapeutic activity of VIEKIRA XR.
HMG-CoA Reductase Inhibitors Atorvastatin
Lovastatin,
simvastatin Potential for myopathy including rhabdomyolysis.
Immunosuppressants Everolimus
Sirolimus
Tacrolimus Increased potential for serious and/or life threatening immunosuppressant associated adverse events.
Non-nucleoside reverse transcriptase inhibitor Efavirenz Co-administration of efavirenz based regimens with paritaprevir, ritonavir plus dasabuvir was poorly tolerated and resulted in liver enzyme elevations.
Phosphodiesterase-5 (PDE5) inhibitor Sildenafil when dosed as Revatio for the treatment of pulmonary arterial hypertension (PAH) There is increased potential for sildenafil-associated adverse events such as visual disturbances, hypotension, priapism, and syncope.
Sedatives/hypnotics Triazolam
Orally administered
midazolam Triazolam and orally administered midazolam are extensively metabolized by CYP3A4. Coadministration of triazolam or orally administered midazolam with VIEKIRA XR may cause large increases in the concentration of these benzodiazepines. The potential exists for serious and/or life threatening events such as prolonged or increased sedation or respiratory depression.
5 WARNINGS AND PRECAUTIONS
5 |
|
